GSK advances in Pfizer consumer health auction as Reckitt quits

NEW YORK/LONDON (Reuters) - GlaxoSmithKline has pulled ahead in a race to buy Pfizer's consumer healthcare business, which the U.S. drugmaker believes could be worth as much as $20 billion, after its main rival Reckitt Benckiser quit the auction.

GSK advances in Pfizer consumer health auction as Reckitt quits
Read More


Bagikan Berita Ini